The present invention relates to the field of diagnostic and therapeutic medical implants and data communication between them.
Communication between diagnostic and/or therapeutic medical device implants within the body can be highly beneficial. One example is the information exchange between an implantable sensor and an implantable pulse generator (IPG), that uses the sensed information for optimizing its operation. Published U.S. Patent Application US 2004-0204744A1, which is incorporated by reference herein, discloses using an intra-body acoustic communication link for this purpose. As taught in that publication, in order to minimize energy consumption, the sensor implant is left deactivated (i.e., not powered on) until an acoustic wave pulse received from another implanted device activates the sensor implant using acoustic switch technology. Two possible transducer configurations applicable for this concept are disclosed in this published application.
Acoustic transducers integrated in implantable medical device are known. For example, U.S. Pat. No. 6,477,406, discloses several acoustic transducer configurations used for listening to sounds produced by the heart. However, these transducers were designed only for receiving acoustic signals, and not for transmitting acoustic signals. Moreover, the transducer configurations of this patent are optimized to low sound frequencies in a range of 5-300 Hz, while for acoustic communication much higher frequencies are used, e.g., in an ultrasonic range of 20 kHz-10 MHz. In particular, U.S. Pat. No. 6,477,406 does not teach an acoustic transducer that can effectively produce ultrasonic transmission or to serve as an effective receiver at high acoustic frequencies.
Acoustic communication was also suggested for data exchange between an implantable device and external unit, such as disclosed in U.S. Pat. No. 5,113,859. However, this patent also does not teach or describe an acoustic transducer capable of performing the communication, nor is there any transducer disclosed or described that is capable of transmitting ultrasonic signals at a level sufficient for activating an acoustic switch and or communicating with a second implant.
The drawings illustrate the design and utility of embodiments of the invention, in which similar elements are referred to by common reference numerals. With the understanding that these drawings depict only exemplary embodiments of the invention, and are not therefore to be considered limiting its scope, the embodiments will be described and explained with additional specificity and detail through the use of the accompanying drawings, in which:
a and 3b illustrate still further alternate embodiments of an acoustic transducer integrated on an end of an implantable acoustic lead, in which the transducer is based on a piezoelectric ceramic bar coupled to a flat surface acting as a membrane.
The present invention is directed to an (active) implantable medical device such as a pacemaker, implantable cardioverter defibrillator (ICD), Cardiac Rhythm Therapy (CRT), a standalone hemodynamic monitor, or implantable drug pump, which communicates with another implanted device (not shown), or an extracorporeal device (not shown), using an acoustic communication link. Towards this end, the active implantable device is provided with an acoustic transducer capable of transmitting an acoustic pulse sufficient for activating an acoustic switch in the receiving device, such as described in U.S. Pat. No. 6,628,989. For this purpose, an acoustic pulse that is at least 0.1 msec wide, and at least a 50 Pa peak pressure is preferred. For example, a pulse of 0.5 msec and 500 Pa may be used in one embodiment. The acoustic transducer is preferably capable of transmitting acoustic pulses at a pressure of at least 0.05 Pa (measured at 20 cm in vitro) and receiving signals of 0.05 Pa. The frequency range at which the system can operate is preferably within a range of 20 KHz-3 MHz. In order to maximize the efficiency of the transducer, it is preferably designed to operate at its resonance frequency.
The acoustic transducer may be constructed on an internal surface of the implantable device housing, typically a hermetically sealed enclosure, with a portion of the enclosure housing wall coupled to the transducer and acting as a vibrating diaphragm. Several examples of such embodiments are disclosed and described in co-pending U.S. patent application Ser. No. 11/287,557, filed Nov. 23, 2005, entitled “Implantable Medical Device With Integrated Acoustic Transducer,” the disclosure of which is hereby incorporated by reference in its entirety.
Integrating the acoustic transducer within the medical device enclosure is practically transparent to the implanting physician. Also in this configuration the hermetic enclosure protects the transducer and its electronics from the environment. However, usually the implantation location of the active medical device is limited due to its size and the wish to minimize the implantation procedure invasiveness. As a result the implantation site can be sub-optimal for acoustic communication. For example, an IPG is most often implanted under the skin beneath the collar bone. Due to anatomy and the physical fact that acoustic waves can not cross the lungs any communication between the IPG and a second implant located within the heart may be sub-optimal.
Implantation of the acoustic lead 300 can be performed using the same catheterization techniques used for implanting IPG electrical leads. However, instead of entering the right atrium (and in some cases the heart right ventricle), the acoustic lead can preferably be located external to the heart, and preferably in a location with a direct “line of sight” between the lead acoustic source and a second implant to be in communication with the transducer. Many of the risks involved in implanting an IPG electrical lead, such as thrombus formation or damage to the heat valve, may be avoided by not entering the heart or passing through the heart valve. The fixation of the acoustic lead 300 may be accomplished, for example, by a radial anchoring of the device to a wall of the vessel using a stent-like device, or with a screw or hook-type fixation to the vessel wall.
Alternatively the lead can be implanted at other positions not via catheterization, for example under the skin, or taking advantage of the cut required for implanting the IPG, the lead can be positioned in the cut and aligned optimally to the implant in order to optimize the acoustic channel. The connection of the said acoustic lead to the IPG can be via a standard electrical feed through of the IPG. The implantation of the acoustic lead can be using the same technique of catheterization used for implanting IPG electrical leads. However, preferably instead of entering the right atrium and in some cases the heart right ventricle, the acoustic lead can be located external to the heart, preferably in a location with a direct line of sight between the lead acoustic source and the second implant. Many of the risks involved in implanting an IPG electrical lead, such as thrombus formation or damage to the heat valve, may be avoided by not entering the heart or passing through the heart valve.
The transducer in
The piezoelectric layer is preferably of a material selected from the group consisting of PVDF and piezoceramic. A transducer based on this design can produce approximately 100 Pa for 100 volts of excitation voltage. Since the transducer is made of a PVDF or a similar material, it can withstand much higher voltages. As a result, the transmission acoustic requirements for activating an acoustic pulse can be easily met with such a transducer at a voltage of several hundreds of volts. The high voltage required can be produced in the IPG or more preferably close to the transducer using a transformer of similar step up voltage device known in the art.
a disclose alternative transducer designs that can substantially reduce the high voltage requirement of the transducer design proposed in
The array can be single sided, as shown in
Since the physical behavior of an array of transducers may vary from that of the single transducer due to the mutual effect imposed by the neighboring cells, the cell members in the array may be connected in parallel to the same driver or may have separate power sources which have different phases and/or voltage amplitude for optimizing the transmitted acoustic pulse. Also, each of the acoustic cell members can have different acoustic response characteristics, e.g. resonance frequency and resonance width, so as to optimize the acoustic response for the specific application.
a and 3b illustrate a transducer that is based on a piezoelectric ceramic bar coupled to a flat surface acting as a membrane. The length of the structure is fixed by a rigid backbone, whereas preferably the entire structure is vibrating at its resonance frequency.
It will be appreciated that the illustrated embodiments are by way of example, and not limitation, and other and further transducer embodiments may be employed within the scope of the inventions disclosed herein.
Piezoelectric materials are well known and the proposed design of the transducer can use any material from the group including: electrostrictive ceramic, piezoelectric ceramic, piezoelectric ceramic-polymer composite and piezoelectric polymers. The proposed transducer design can employ one or more piezoelectric discs with an electrode there between discs, e.g., two discs surrounding an electrode. This configuration allows for electrical connection of the piezoelectric discs in series, in parallel, or in a combination of the two, using electrical contacts to the disc electrodes. This configuration allows optimization of the transducer for specific tasks. For example, the voltage available in an IPG is usually relatively low, produced from its internal 2-3 volts battery. For transmitting an acoustic signal required for activating an acoustic switch, a relatively high voltage may be required (for example, several hundred volts).
Using multiple, thin discs of piezoelectric material connected in parallel will produce the equivalent acoustic power of a single, thicker disc, but at a substantially lower voltage. For example, two piezoelectric discs that are each 0.5 mm thick, connected in parallel, will produce a similar acoustic power as a 1 mm thick piezoelectric disc at half the voltage. However, if one wishes to optimize the receiving sensitivity of the transducer, serial connection of the thin piezoelectric discs will result in a higher voltage signal per a given acoustic signal, than a single thick disk. The ceramics may also be connected anti-parallel, to produce a bending moment as a piezoelectric bimorph.
For producing the transmitted acoustic signal, the proposed acoustic transducer should be efficient and durable. Preferably, the transducers should work at their resonance frequency in order to optimize the efficiency and sensitivity of the transducer. The resonance frequency of the transducer depends on several parameters, including the type, thickness and diameter of the piezoelectric material, the material and thickness of the diaphragm (230), and the material, thickness, and height of the rigid wall 240, as is known by those skilled in the art of acoustic transducer design.
For optimizing the receiving sensitivity of the transducer, a separate piece of piezoelectric material with relatively high acoustic sensitivity can be used, such as a layer of PVDF (not shown), attached to the piezoelectric ceramic disc/s used for transmission. Another way to improve the receiving signal to noise is by integrating an amplifier close to the structure or within the lead in order to minimize any parasitic effects and noises.
All the above-disclosed, implantable transducers can, in addition to activation and communication with a second implant, also be used for acoustically energizing and charging the second implant. Preferably, the acoustic lead design of
Preferably, the battery capacity of the second implant is such that charging will not be required for a duration longer than that of the IPG battery. Upon the replacement of the IPG controller, the acoustic lead can be connected to an external power source for charging the second implant battery. Alternatively, an acoustic catheter can be used for acoustically charging the second implant. This catheter can be built similar to the acoustic lead, with an acoustic transducer at its tip or by serving as an acoustic wave-guide. The acoustic catheter can be introduced to the body in a similar technique used for right heart catheterization. This procedure is usually carried out via the femoral vein and internal jugular subclavian vein, using a standard guide wire based catheterization or by a floating balloon (e.g., a Swan-Ganz catheter). The procedure can be guided using fluoroscopy or pressure pattern measurements. Since the acoustic source on the catheter can be located very close to the second implant, the charging process is preferably very efficient and local.
The transducer designs disclosed herein are preferably encapsulated as required for an implantable active medical device. Methods of manufacturing electrical leads for IPG are well known in the art, and one may use such known methods, and materials such as polyurethane or silicone extrusion, for encapsulating the transducer and its supporting electronics. Alternatively, the transducer may be encapsulated in a metallic sealed case filled with inert liquid (e.g. silicone oil) and having at least one flexible face. Such a metallic box can be made from any biocompatible metal such as titanium, tantalum, stainless steel, gold or platinum with a flexible membrane preferably less the 0.5 mm thick and more preferably less than 0.05 mm thick.
The present application claims the benefit of priority under 35 U.S.C § 119 to U.S. Provisional Application 60/633,063, filed Dec. 3, 2004, the contents of which are hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
2967957 | Massa | Jan 1961 | A |
3568661 | Franklin | Mar 1971 | A |
3676720 | Libby et al. | Jul 1972 | A |
3757770 | Brayshaw et al. | Sep 1973 | A |
3792204 | Murayama et al. | Feb 1974 | A |
3798473 | Murayama et al. | Mar 1974 | A |
3832580 | Yamamuro et al. | Aug 1974 | A |
3894198 | Murayama et al. | Jul 1975 | A |
3940637 | Ohigashi et al. | Feb 1976 | A |
3978353 | Kinoshita | Aug 1976 | A |
4008408 | Kodama | Feb 1977 | A |
4051455 | Fowler | Sep 1977 | A |
4056742 | Massa | Nov 1977 | A |
4064375 | Russell et al. | Dec 1977 | A |
4096756 | Alphonse | Jun 1978 | A |
4127110 | Bullara | Nov 1978 | A |
4170742 | Itagaki et al. | Oct 1979 | A |
4181864 | Etzold | Jan 1980 | A |
4227407 | Drost | Oct 1980 | A |
4281484 | Massa | Aug 1981 | A |
4431873 | Dunn et al. | Feb 1984 | A |
4433400 | De Reggi et al. | Feb 1984 | A |
4456850 | Inoue et al. | Jun 1984 | A |
4481950 | Duggan | Nov 1984 | A |
4517665 | De Reggi et al. | May 1985 | A |
4519401 | Ko et al. | May 1985 | A |
4541431 | Ibrahim et al. | Sep 1985 | A |
4558249 | Lerch et al. | Dec 1985 | A |
4580074 | Gilman | Apr 1986 | A |
4593703 | Cosman | Jun 1986 | A |
4600855 | Strachan | Jul 1986 | A |
4642508 | Suzuki et al. | Feb 1987 | A |
4653036 | Harris et al. | Mar 1987 | A |
4653508 | Cosman | Mar 1987 | A |
4660568 | Cosman | Apr 1987 | A |
4672976 | Kroll | Jun 1987 | A |
4676255 | Cosman | Jun 1987 | A |
4677337 | Kleinschmidt et al. | Jun 1987 | A |
4781715 | Wurzel | Nov 1988 | A |
4793825 | Benjamin et al. | Dec 1988 | A |
4835435 | Yeung et al. | May 1989 | A |
4846191 | Brockway et al. | Jul 1989 | A |
4911172 | Bui et al. | Mar 1990 | A |
4958100 | Crawley et al. | Sep 1990 | A |
5012815 | Bennett, Jr. et al. | May 1991 | A |
5024224 | Engebretson | Jun 1991 | A |
5088576 | Potthoff et al. | Feb 1992 | A |
5113859 | Funke | May 1992 | A |
5160870 | Carson et al. | Nov 1992 | A |
5178153 | Einzig | Jan 1993 | A |
5283397 | Pavlovic | Feb 1994 | A |
5289821 | Swartz | Mar 1994 | A |
5300875 | Tuttle | Apr 1994 | A |
5314457 | Jeutter et al. | May 1994 | A |
5339290 | Greenstein | Aug 1994 | A |
5367500 | Ng | Nov 1994 | A |
5381067 | Greenstein et al. | Jan 1995 | A |
5381386 | Lum et al. | Jan 1995 | A |
5410587 | Grunwell | Apr 1995 | A |
5411551 | Winston et al. | May 1995 | A |
5423334 | Jordan | Jun 1995 | A |
5438553 | Wilson et al. | Aug 1995 | A |
5476488 | Morgan et al. | Dec 1995 | A |
5483501 | Park et al. | Jan 1996 | A |
5488954 | Sleva et al. | Feb 1996 | A |
5495137 | Park et al. | Feb 1996 | A |
5554177 | Kieval et al. | Sep 1996 | A |
5562714 | Grevious | Oct 1996 | A |
5571152 | Chen et al. | Nov 1996 | A |
5628782 | Myers | May 1997 | A |
5679026 | Fain et al. | Oct 1997 | A |
5704352 | Tremblay et al. | Jan 1998 | A |
5733313 | Barreras, Sr. et al. | Mar 1998 | A |
5735887 | Barreras, Sr. et al. | Apr 1998 | A |
5741316 | Chen et al. | Apr 1998 | A |
5749909 | Schroeppel et al. | May 1998 | A |
5757104 | Getman et al. | May 1998 | A |
5792195 | Carlson et al. | Aug 1998 | A |
5807258 | Cimochowski et al. | Sep 1998 | A |
5825117 | Ossmann et al. | Oct 1998 | A |
5832924 | Archibald et al. | Nov 1998 | A |
5833603 | Kovacs et al. | Nov 1998 | A |
5843135 | Weijand et al. | Dec 1998 | A |
5873835 | Hastings et al. | Feb 1999 | A |
5879283 | Adams et al. | Mar 1999 | A |
5935081 | Kadhiresan | Aug 1999 | A |
5956292 | Bernstein | Sep 1999 | A |
5957950 | Mockros et al. | Sep 1999 | A |
5967986 | Cimochowski et al. | Oct 1999 | A |
6044298 | Salo et al. | Mar 2000 | A |
6053873 | Govari et al. | Apr 2000 | A |
6058329 | Salo et al. | May 2000 | A |
6068589 | Neukermans | May 2000 | A |
6082367 | Greeninger et al. | Jul 2000 | A |
6140740 | Porat et al. | Oct 2000 | A |
6141588 | Cox et al. | Oct 2000 | A |
6185452 | Schulman et al. | Feb 2001 | B1 |
6223081 | Kerver | Apr 2001 | B1 |
6409675 | Turcott | Jun 2002 | B1 |
6475170 | Doron et al. | Nov 2002 | B1 |
6477406 | Turcott | Nov 2002 | B1 |
6480733 | Turcott | Nov 2002 | B1 |
6486588 | Doron et al. | Nov 2002 | B2 |
6504289 | Toda et al. | Jan 2003 | B2 |
6527729 | Turcott | Mar 2003 | B1 |
6537200 | Leysieffer et al. | Mar 2003 | B2 |
6554761 | Puria et al. | Apr 2003 | B1 |
6575894 | Leysieffer et al. | Jun 2003 | B2 |
6600949 | Turcott | Jul 2003 | B1 |
6628989 | Penner et al. | Sep 2003 | B1 |
6629922 | Puria et al. | Oct 2003 | B1 |
6643548 | Mai et al. | Nov 2003 | B1 |
6645145 | Dreschel et al. | Nov 2003 | B1 |
6654638 | Sweeney | Nov 2003 | B1 |
6671550 | Iaizzo et al. | Dec 2003 | B2 |
6697674 | Leysieffer | Feb 2004 | B2 |
6740076 | Hoben et al. | May 2004 | B2 |
6741714 | Jensen | May 2004 | B2 |
6763722 | Fjield et al. | Jul 2004 | B2 |
6764446 | Wolinsky et al. | Jul 2004 | B2 |
6772490 | Toda | Aug 2004 | B2 |
6792308 | Corbucci | Sep 2004 | B2 |
7016739 | Bange et al. | Mar 2006 | B2 |
7024248 | Penner et al. | Apr 2006 | B2 |
7035684 | Lee | Apr 2006 | B2 |
7107103 | Schulman et al. | Sep 2006 | B2 |
7114502 | Schulman et al. | Oct 2006 | B2 |
7115096 | Siejko et al. | Oct 2006 | B2 |
7118531 | Krill | Oct 2006 | B2 |
7123962 | Siejko et al. | Oct 2006 | B2 |
7127290 | Girouard et al. | Oct 2006 | B2 |
7176602 | Schlenke | Feb 2007 | B2 |
7198603 | Penner et al. | Apr 2007 | B2 |
7220232 | Suorsa et al. | May 2007 | B2 |
7228175 | Jain et al. | Jun 2007 | B2 |
7236821 | Cates | Jun 2007 | B2 |
7248923 | Maile et al. | Jul 2007 | B2 |
7260429 | Siejko et al. | Aug 2007 | B2 |
7273457 | Penner | Sep 2007 | B2 |
7283874 | Penner | Oct 2007 | B2 |
7335169 | Thompson et al. | Feb 2008 | B2 |
7431699 | Siejko et al. | Oct 2008 | B2 |
20040106954 | Whitehurst et al. | Jun 2004 | A1 |
20040122484 | Hatlestad et al. | Jun 2004 | A1 |
20040127792 | Siejko et al. | Jul 2004 | A1 |
20040138572 | Thiagarajan | Jul 2004 | A1 |
20040204744 | Penner et al. | Oct 2004 | A1 |
20040230249 | Haefner | Nov 2004 | A1 |
20050131472 | Ding et al. | Jun 2005 | A1 |
20050137490 | Scheiner et al. | Jun 2005 | A1 |
20050149138 | Min et al. | Jul 2005 | A1 |
20060009818 | Von Arx et al. | Jan 2006 | A1 |
20060142819 | Penner et al. | Jun 2006 | A1 |
20060149329 | Penner | Jul 2006 | A1 |
20070049977 | Von Arx et al. | Mar 2007 | A1 |
20070142728 | Penner et al. | Jun 2007 | A1 |
20080021289 | Zhang et al. | Jan 2008 | A1 |
20080021509 | Mi et al. | Jan 2008 | A1 |
20080021510 | Mi et al. | Jan 2008 | A1 |
Number | Date | Country |
---|---|---|
3222349 | Jan 1984 | DE |
0798016 | Oct 1997 | EP |
0897690 | Feb 1999 | EP |
1151719 | Nov 2001 | EP |
WO 8303345 | Oct 1983 | WO |
WO 9701986 | Jan 1997 | WO |
WO 9733513 | Sep 1997 | WO |
WO 9735636 | Oct 1997 | WO |
WO 9747236 | Dec 1997 | WO |
WO 9826716 | Jun 1998 | WO |
WO 9829030 | Jul 1998 | WO |
WO 9926530 | Jun 1999 | WO |
WO 9959460 | Nov 1999 | WO |
WO 0016686 | Mar 2000 | WO |
WO 03068047 | Aug 2003 | WO |
WO 2004091719 | Oct 2004 | WO |
WO 2006069215 | Jun 2006 | WO |
Number | Date | Country | |
---|---|---|---|
60633063 | Dec 2004 | US |